Document is current
Any future updates will be listed below
-
Authors
Peng, Lun-Xi
Jie, Guang-Ling
Li, An-Na
Liu, Si-Yang
Sun, Hao
Zheng, Mei-Mei
Zhou, Jia-Ying
Zhang, Jia-Tao
Zhang, Xu-Chao
Zhou, Qing
Zhong, Wen-Zhao
Yang, Jin-Ji
Tu, Hai-Yan
Su, Jian
Yan, Hong-Hong
Wu, Yi-Long http://orcid.org/0000-0002-3611-0258
-
Funding
Funding for this research was provided by:
the National Key R&D Program of China (2016YFC1303800)
the Special Fund of Public Interest, the National Health and Family Control Committee (201402031)
- License Information
-
More Information
Article History
Received: 18 September 2021
Accepted: 29 October 2021
First Online: 10 November 2021
Declarations
:
: The study was approved by the Research Ethics Committee of Guangdong Provincial People’s Hospital (EC Number: 2013185H[R2]).
: Not applicable.
: YLW received honoraria from AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, Hengrui, MSD, Pfizer, Roche, and Sanofi; had a consulting or advisory role with AstraZeneca, Boehringer Ingelheim, Novartis, Merck, MSD, Roche, and Takeda; and received institutional research funding from AstraZeneca, Boehringer Ingelheim, BMS, Hengrui, Pfizer, and Roche. The authors declare that they have no competing interests.
